Literature DB >> 8862960

Concepts in risk-benefit assessment. A simple merit analysis of a medicine?

R Edwards1, B E Wiholm, C Martinez.   

Abstract

The term 'benefit-risk ratio' is often used as a general term linked to the use of a medicine. To balance risk and benefit is, however, a very complex exercise. For most medicines the benefits are limited to a few indications and for an individual patient there is usually only a single benefit sought but the potential risks are multiple. Perceptions of risks versus benefits are influenced to a great extent by the context in which they occur. Thus, perception of risk may be different to actual risk. In the end in any given situation, the acceptable risk-to-benefit balance is an individual judgement on the part of the patient or the prescriber. For newer medicines, where there is likely to be limited experience, conservative estimates of the overall merit seem preferable so that the prescriber will use the drug critically. Subsequently, re-evaluation of the risk-to-benefit balance is necessary as greater knowledge of efficacy and adverse effects is acquired. It is possible to provide a general 'principle of threes' structure for a merit assessment based upon the concepts of seriousness, duration and incidence as related to disease indication, disease amelioration by a medicine, and the adverse effects ascribed to the medicine. This allows a rapid first comparison of medicines for a given indication. In using this general conceptual model in a transparent fashion for a given hypothesis and context, it is possible to identify the essential data used and assumptions involved that make up a merit statement. The quality and value, particularly of risk data, is problematic. Risk perception is an issue that needs to be clearly identified alongside a merit analysis. A simple merit assessment should pave the way for more focused studies.

Entities:  

Mesh:

Year:  1996        PMID: 8862960     DOI: 10.2165/00002018-199615010-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  18 in total

1.  Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review.

Authors:  S Sauerland; M Nagelschmidt; P Mallmann; E A Neugebauer
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

2.  Labelling and 'Dear Doctor' letters: are they noncommittal?

Authors:  A C Kees van Grootheest; I Ralph Edwards
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  What is drug safety?: celebrating 20 years of the Drug Safety journal.

Authors:  I Ralph Edwards
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 4.  Pharmacovigilance in the pharmaceutical industry.

Authors:  J C Talbot; B S Nilsson
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

Review 5.  The challenge of effectively communicating risk-benefit information.

Authors:  I R Edwards; B Hugman
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.606

Review 6.  Integration of PKPD relationships into benefit-risk analysis.

Authors:  Francesco Bellanti; Rob C van Wijk; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-07-29       Impact factor: 4.335

Review 7.  Comparative tolerability and efficacy of treatments for impotence.

Authors:  W Meinhardt; R F Kropman; P Vermeij
Journal:  Drug Saf       Date:  1999-02       Impact factor: 5.606

Review 8.  Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits?

Authors:  B Lindelöf
Journal:  Drug Saf       Date:  1999-04       Impact factor: 5.606

9.  Glucose intolerance with atypical antipsychotics.

Authors:  Karin Hedenmalm; Staffan Hägg; Malin Ståhl; Orjan Mortimer; Olav Spigset
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 10.  Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales.

Authors:  Dianne C Berry; D K Raynor; Peter Knapp; Elisabetta Bersellini
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.